Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.

Vivas I, Iribarren K, Lozano T, Cano D, Lasarte-Cia A, Chocarro S, Gorraiz M, Sarobe P, Hervás-Stubbs S, Bilbao JI, Casares N, Lasarte JJ.

J Vasc Interv Radiol. 2019 Jul;30(7):1098-1105. doi: 10.1016/j.jvir.2019.02.023. Epub 2019 May 14.

PMID:
31101416
2.

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y.

3.

Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.

4.

Anticancer effects of anti-CD47 immunotherapy in vivo.

Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G.

Oncoimmunology. 2018 Dec 11;8(3):1550619. doi: 10.1080/2162402X.2018.1550619. eCollection 2019.

PMID:
30723582
5.

Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.

Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I.

Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019.

6.

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.

Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Dis. 2018 Oct 23;9(11):1086. doi: 10.1038/s41419-018-1127-3.

7.

Epigenetic anticancer agents cause HMGB1 release in vivo.

Liu P, Zhao L, Loos F, Iribarren K, Kepp O, Kroemer G.

Oncoimmunology. 2018 Feb 14;7(6):e1431090. doi: 10.1080/2162402X.2018.1431090. eCollection 2018.

8.

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.

Lasarte-Cia A, Lozano T, Pérez-González M, Gorraiz M, Iribarren K, Hervás-Stubbs S, Sarobe P, Rabal O, Cuadrado-Tejedor M, García-Osta A, Casares N, Lasarte JJ.

Front Immunol. 2018 Jan 25;9:68. doi: 10.3389/fimmu.2018.00068. eCollection 2018.

9.

eIF2α phosphorylation is pathognomonic for immunogenic cell death.

Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G.

Cell Death Differ. 2018 Aug;25(8):1375-1393. doi: 10.1038/s41418-017-0044-9. Epub 2018 Jan 22.

PMID:
29358668
10.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2018 Jan;25(1):227-228. doi: 10.1038/cdd.2017.148. Epub 2017 Nov 10.

11.

Identification of pharmacological agents that induce HMGB1 release.

Liu P, Zhao L, Loos F, Iribarren K, Lachkar S, Zhou H, Gomes-da-Silva LC, Chen G, Bezu L, Boncompain G, Perez F, Zitvogel L, Kepp O, Kroemer G.

Sci Rep. 2017 Nov 2;7(1):14915. doi: 10.1038/s41598-017-14848-1.

12.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
13.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

14.

Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.

Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G.

Oncoimmunology. 2016 Jun 9;5(7):e1177692. doi: 10.1080/2162402X.2016.1177692. eCollection 2016 Jul.

15.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2016 Dec;23(12):2031-2041. doi: 10.1038/cdd.2016.86. Epub 2016 Sep 2. Erratum in: Cell Death Differ. 2017 Nov 10;:.

16.

Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.

Dajon M, Iribarren K, Cremer I.

Immunobiology. 2017 Jan;222(1):89-100. doi: 10.1016/j.imbio.2016.06.009. Epub 2016 Jun 14. Review.

PMID:
27349597
17.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

18.

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.

Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3.

19.

Dual roles of TLR7 in the lung cancer microenvironment.

Dajon M, Iribarren K, Cremer I.

Oncoimmunology. 2015 Jan 9;4(3):e991615. eCollection 2015 Mar.

20.

TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.

Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, Younes M, Dieu-Nosjean MC, Fridman WH, Sautès-Fridman C, Cremer I.

Cancer Res. 2014 Sep 15;74(18):5008-18. doi: 10.1158/0008-5472.CAN-13-2698. Epub 2014 Jul 29.

Supplemental Content

Loading ...
Support Center